Outcome of Annual General Meeting of May 29, 2018
Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
First quarter 2018 report
Innate Pharma to hold its Annual General Meeting of Shareholders on May 29, 2018 and the release of its Reference document (in french)
Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN
New preclinical data further support ongoing programs and highlight next generation of immunotherapies
Upcoming investor conferences
Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)
Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
Innate Pharma Hosts R&D Day Today in London
